XML 140 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Equity (Tables)
 12 Months Ended
Dec. 31, 2020
Disclosure of equity [abstract]  
Schedule disclosing information related to movement in the share capital


(USD millions)


Jan 1, 2018
Movement

in year


Dec 31, 2018
Movement

in year


Dec 31, 2019
Movement

in year


Dec 31, 2020
Share capital
969
– 25
944
– 8
936
– 23
913
Treasury shares
– 100
31
– 69
– 11
– 80
27
– 53
Outstanding share capital
869
6
875
– 19
856
4
860
Schedule disclosing information related to movement in the shares
2020
2019
2018


Number of outstanding shares

(in millions)




Note
Total

Novartis

shares
Total

treasury

shares 1
Total

outstanding

shares
Total

Novartis

shares
Total

treasury

shares 1
Total

outstanding

shares
Total

Novartis

shares
Total

treasury

shares 1
Total

outstanding

shares
Balance at beginning of year
2 527.3
– 262.3
2 265.0
2 550.6
– 239.4
2 311.2
2 616.8
– 299.3
2 317.5
Shares canceled for capital

reduction  2




– 60.3


60.3




– 23.3


23.3




– 66.2


66.2


Shares acquired to be

canceled  3






– 32.6


– 32.6




– 60.3


– 60.3




– 23.3


– 23.3
Other share purchases  4
– 1.7
– 1.7
– 1.7
– 1.7
– 1.2
– 1.2
Exercise of options

and employee transactions  5


18.9




14.7


14.7




5.5


5.5




7.8


7.8
Equity-based compensation  5
11.0
11.0
9.4
9.4
7.4
7.4
Shares delivered to Alcon

employees






0.4


0.4




0.9


0.9






Other share sales
3.0
3.0
Total movements
– 60.3
52.1
– 8.2
– 23.3
– 22.9
– 46.2
– 66.2
59.9
– 6.3
Balance at end of year
2 467.0
– 210.2
2 256.8
2 527.3
– 262.3
2 265.0
2 550.6
– 239.4
2 311.2
 1  Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use.
 2  Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.
 3  Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date
 4  Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans
 5  Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans.
 
Schedule disclosing information related to Dividend
2020
2019
2018
Dividend per share (in CHF)
2.95
2.85
2.80
Total dividend payment

(in USD billion)


7.0


6.6


7.0
Schedule disclosing information related treasury shares movements
2020
2019
2018






Note
Number of

outstanding

shares

(in millions)




Equity impact

USD m
Number of

outstanding

shares

(in millions)




Equity impact

USD m
Number of

outstanding

shares

(in millions)




Equity impact

USD m
Shares acquired to be canceled  1
– 32.6
– 2 897
– 60.3
– 5 351
– 23.3
– 1 859
Other share purchases  2
– 1.7
– 159
– 1.7
– 160
– 1.2
– 114
Purchase of treasury shares
– 34.3
– 3 056
– 62.0
– 5 511
– 24.5
– 1 973
Exercise of options and employee transactions  3
18.9
14.7
806
5.5
210
7.8
434
Equity-based compensation  4
11.0
730
9.4
833
7.4
756
Shares delivered to Alcon employees
0.4
30
0.9
18
Other share sales
3.0
263
Total
– 8.2
– 1 490
– 46.2
– 4 450
– 6.3
– 520
 1  Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date
 2  Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans
 3  Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.
 4  Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.